
Pacific Biosciences of California, Inc.: updates and filings
Price
$1.83
November 18, 2026Market cap $553M
What Ploutos Investor adds for Pacific Biosciences of California
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 25% since Nov 5, 2026, when the 10-Q these figures come from was filed ($2.43 then, $1.83 on Nov 18, 2026). The figures date from before that move.10-Q
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 4, 2026next Feb 5, 2027
A rough estimate from when it has reported before, which has varied. The company announces the date itself.
November 2026
August 2026
May 2026
March 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 10, 2026Material agreement enteredForm8-K
- Nov 9, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 6, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 4, 2026Results of operations, officer or director changeForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 7, 2026Shares registered for employeesFormS-8
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 5, 2026Results of operations, restructuring costs, officer or director change, Regulation FD disclosureForm8-K
- Jul 9, 2026Officer or director changeForm8-K
- Jun 4, 2026Officer or director change, shareholder voteForm8-K
- May 27, 2026Conflict minerals reportFormSD
- May 22, 2026Additional annual meeting materialFormDEFA14A
- May 8, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 7, 2026Results of operationsForm8-K
- Apr 23, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 23, 2026Additional annual meeting materialFormDEFA14A
- Apr 23, 2026Annual meeting proxy statementFormDEF 14A
- Mar 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 6, 2026Officer or director change, Regulation FD disclosureForm8-K
- Mar 5, 2026Officer or director change, Regulation FD disclosureForm8-K
- Feb 25, 2026Shelf registration for future offeringsFormS-3ASR
- Feb 25, 2026Shares registered for employeesFormS-8
- Feb 25, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 12, 2026Results of operationsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 10, 2026 | 8-K | Material agreement entered | Document |
| Nov 9, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 6, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 4, 2026 | 8-K | Results of operations, officer or director change | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 7, 2026 | S-8 | Shares registered for employees | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 5, 2026 | 8-K | Results of operations, restructuring costs, officer or director change, Regulation FD disclosure | Document |
| Jul 9, 2026 | 8-K | Officer or director change | Document |
| Jun 4, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 27, 2026 | SD | Conflict minerals report | Document |
| May 22, 2026 | DEFA14A | Additional annual meeting material | Document |
| May 8, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 7, 2026 | 8-K | Results of operations | Document |
| Apr 23, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 23, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 23, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 6, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Mar 5, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Feb 25, 2026 | S-3ASR | Shelf registration for future offerings | Document |
| Feb 25, 2026 | S-8 | Shares registered for employees | Document |
| Feb 25, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 12, 2026 | 8-K | Results of operations | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jul 28, 2004.
The full analysis
What do Pacific Biosciences of California's filings show?
The filings are where every one of Pacific Biosciences of California's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.